- Key oral presentations highlight new data from AbbVie (ABBV)'s novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results